Lenalidomide and genetic profiling in myeloma, T-cell immunotherapy upregulates AML cell MHC-class II, and young fecal microbiota rejuvenate HSCs
Blood Podcast
00:00
Lenalidomide Maintenance for Multiple Myeloma Patients
The future for myeloma is a risk-adapted therapy. Lenalidomide should be the standard of care after transplant in patients with standard risk or single-hit abnormality. New drugs and drug combinations need to be explored, authors say.
Transcript
Play full episode
